Author + information
- aZena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York
- bCenter for Cardiovascular Research, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- ↵∗Address for correspondence:
Dr. Valentin Fuster, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029.
The inaugural edition of JACC: Basic to Translational Science, the newest of the JACC family of journals—the only open access JACC journal—was published online March 2, 2016. Given the recent proliferation of cardiovascular journals, it is appropriate to ask how JACC: Basic to Translational Science fits into the growing JACC family of journals, as well as how it adds to the literature. The answer to both of these questions is that there has never been a scientific literary home for cardiovascular “translationalists” who wish to publish research that stands at the crossroads of basic and clinical research. JACC: Basic to Translational Science seeks to publish studies that will lead to new therapies, tracing the arc of scientific discovery from early preclinical studies all the way through phase I and II clinical trials. More established basic and clinical journals often quickly dismiss translational studies for perceived lack of mechanistic depth and/or because they involve too few patients to engender confidence that phase III clinical trials will validate the findings. The editors of JACC: Basic to Translational Science believe that new ideas cannot grow to become new therapies unless they see the light of day, and that one cannot move to phase III clinical trials without passing through smaller phase I and II studies. During the first year, JACC: Basic to Translational Science published a series of outstanding preclinical, early-phase transitional clinical studies and novel translational methods. Importantly, 57% of the papers published during the first year were from domestic submissions and 43% were from international submissions, which attests to the global nature of cardiovascular translational research.
The second goal of JACC: Basic to Translational Science is to create an open access journal that serves as a platform for accelerating the translation of new scientific discoveries into new therapies that improve clinical outcomes for patients afflicted with or at risk of developing cardiovascular disease. Translational science exemplifies “big science,” insofar as it requires the synergistic cooperation between basic and clinical investigators in academia and industry, patients and their families, patient advocacy groups, and governmental funding and regulatory agencies to evaluate and develop new therapies. No one investigator can acquire all the requisite skills needed to conduct this type of research. To this end, one of the overarching goals of JACC: Basic to Translational Science is to become both a forum and a learning center for cardiovascular investigators in academia and industry, patients and families affected by heart disease, the National Heart, Lung, and Blood Institute, and the U.S. Food and Drug Administration, in order to help advance translational cardiovascular medicine. During the inaugural year, JACC: Basic to Translational Science published a series of well-received state-of-the-art papers, uniquely themed “how to” papers in the Translational Toolbox section of the journal, and a number of interesting and provocative papers on various aspects of translational medicine in the Translational Perspectives section.
To publish a journal that effectively covers the cardiovascular translational research space, from new molecules and devices, to animal models, to early-phase transitional trials, requires the assemblage of a group of editors with unique and varied skillsets. JACC: Basic to Translational Science is fortunate to have a committed editorial board and reviewers, who in addition to being accomplished investigators, are also “translationalists,” including: Deputy Editor Kristen Newby; Associate Editors Brian Annex, Nanette Bishopric, Dan Kelly, Peter Libby, W. Robb MacLellan, Eva van Rooij, and Gordon Tomaselli; Senior Guest Editor Robert Roberts; Statistical Editor Eric Novak; Social Media Editors Reza Ardehali and Meena S. Madhur; Journal Watch editors Nicholas Leeper, Rebecca Levit, and John J. Ryan; Managing Editor Courtney Stuntz; and the 177 reviewers who provided their time and expertise to elevate the science in the journal. The editorial board is committed to publishing the highest quality translational science, but is also unafraid of the unique challenges that are inherent in publishing new ideas and early-phase discoveries.
As the latest addition to the JACC family of journals, JACC: Basic to Translational Science complements both the parent journal and the other sister journals by providing a scientific home for translational research studies that do not necessarily fit within the clinical context of the more established JACC journals. We also believe that JACC: Basic to Translational Science uniquely extends the scientific reach of the JACC family of journals by providing a new journalistic home that fosters the arc of translational discovery from “molecules to man,” with the goal of improving outcomes for patients with cardiovascular disease.
- American College of Cardiology Foundation